Sodium oxybate intolerance associated with familial serum acylcarnitine elevation
- PMID: 23319908
- PMCID: PMC3525992
- DOI: 10.5664/jcsm.2346
Sodium oxybate intolerance associated with familial serum acylcarnitine elevation
Abstract
Our case describes clinical features of two families defined by joint phenotypes: sodium oxybate intolerance and elevated serum acylcarnitines. Oxybate intolerance variably presents as either cervical dystonia or sleep-related eating disorder. Our objective is to identify biological markers which predict a poor response to sodium oxybate as a treatment for disturbed sleep. Familial inheritance pattern, genotype analysis, multiorgan system involvement, and response to treatment suggest the presence of a secondary cause of fatty oxidation defect, i.e., mitochondrial disorder. Our case report supports the possible conclusion that variance in human mitochondrial metabolism may affect sodium oxybate tolerability.
References
-
- Russell IJ, Perkins AT, Michalek JE, et al. Sodium oxybate relives pain and improves function in fibromyalgia syndrome. Arthritis Rheum. 2009;60:299–309. - PubMed
-
- Aisen ML, Dietz MA, Rossi P, et al. Clinical and pharmacokinetic aspects of high dose baclofen therapy. J Am Paraplegia Soc. 1992;15:211–6. - PubMed
-
- Kemmel V, Miehe M, Roussel G, et al. Immunohistochemical localization of a GHB receptor-like protein isolated from rat brain. J Comp Neurol. 2006;498:508–24. - PubMed
-
- Latini A, da Silva CG, Ferreira GC, et al. Mitochondrial energy metabolism is markedly impaired by d-2 hydroxyglutaric acid in rat tissues. Mol Genet Metab. 2005;86:188–99. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
